5月21日，药明合联盘中下跌3.03%，报55.95港元/股，成交额1.48亿港元。
药明合联所在的生命科学工具和服务行业中，个股表现分化，其中昭衍新药涨6.06%，药明康德涨1.62%，晶泰控股涨0.76%，药明生物跌1.03%，英矽智能跌4.78%。
药明合联是一家主要从事抗体偶联药物（ADC）及其他生物偶联药物的全面合同研究、开发及制造组织（CRDMO）服务的投资控股公司，业务覆盖国内市场、北美、欧洲和世界其他地区。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.